Report cover image

Middle East and Turkey Hemophilia Treatment Market, By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), By Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and B

Publisher Coherent Market Insights
Published Mar 24, 2025
Length 230 Pages
SKU # CMI20004804

Description

Hemophilia is rare disorder, in which the blood does not clot properly, and Bleeding after an injury takes longer duration to clot. This condition is well treated with medications such as recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Generally hemophilia occurs in middle age and geriatric population, and in women after child birth. Hemophilia is characterized by the lower levels of factors in the blood that results in constant bleeding for longer duration after an injury.

Market Dynamics

Increasing adoption of inorganic growth strategies such as partnership by key market players, in order to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in March 2021, Takeda Pharmaceutical Company Limited., a pharmaceutical company, announced it had entered into a strategic partnership with Enzyre, developer of diagnostic technology, to accelerate the development of Enzyre’s proprietary platform named Enzypad to enable patients to test their blood coagulationat their home.

Increasing adoption of organic growth strategies such product launches by key market players, in oder to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, in November 2022, UniQure, a pharmaceutical company, announced the U.S. Food and Drug Administration approved the first gene therapy Hemgenix for the treatment of adults with hemophilia B that is currently used in factor IX prophylaxis therapy, or has current or historical life-threatening hemorrhage. Hemophilia B is a rare, lifelong bleeding disorder caused by a single gene defect that results in insufficient production of factor IX, a protein produced by the liver that aids in the formation of blood clots.

Key features of the study:
  • This report provides in-depth analysis of the Middle East and Turkey hemophilia treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Middle East and Turkey hemophilia treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
  • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Middle East and Turkey hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Turkey hemophilia treatment market
Detailed Segmentation:
  • Middle East and Turkey Hemophilia Treatment Market, By Product Type
  • Recombinant Coagulation Factor
  • Plasma Derived Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
  • Middle East and Turkey Hemophilia Treatment Market, By Disease Indication
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Middle East and Turkey Hemophilia Treatment Market, By Country
  • Turkey
  • Egypt
  • Israel
  • Saudi Arabia
  • UAE
  • Rest of Middle East
  • Company Profiles
  • Takeda Pharmaceutical Company Limited.
  • Sanofi S.A.
  • Octapharma AG
  • Swedish Orphan Biovitrum AB
  • Baxter
  • Biogen Inc.
  • Bayer AG
  • CSL Behring
  • Ferring B.V.
  • Pfizer, Inc.
  • Kedrion
  • Novo Nordisk A/S
  • Grifols S.A.
  • Sangamo Therapeutics, Inc.
  • Spark Therapeutics, Inc.

Table of Contents

230 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Product Type
Market Snapshot, By Disease Indication
Market Snapshot, By Country
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Attractiveness Analysis
Market Opportunities
Product Launches
Merger, Acquisition, Collaborations
Regulatory Guideline and Compliances
Key Developments
PEST Analysis
Technology Landscape
PORTER’s Analysis
Pricing Analysis
4. Middle East and Turkey Hemophilia Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. Middle East and Turkey Hemophilia Treatment Market, By Product Type, 2020 – 2032, (US$ Million)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
Recombinant Coagulation Factor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
Plasma Derived Coagulation Factor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
Antifibrinolytic Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
Desmopressin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
6. Middle East and Turkey Hemophilia Treatment Market, By Disease Indication, 2020 – 2032, (US$ Million)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
Hemophilia A
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
Hemophilia B
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
Hemophilia C
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
7. Middle East and Turkey Hemophilia Treatment Market, By Country, 2020 – 2032, (US$ Million)
Introduction
Market Share Analysis, By Country, 2025 and 2032 (%)
Y-o-Y Growth Analysis, For Regions, 2021–2032
Regional Trends
Turkey
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2020 - 2032, (US$ Million)
Egypt
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2020 - 2032, (US$ Million)
Israel
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2020 - 2032, (US$ Million)
Saudi Arabia
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2020 - 2032, (US$ Million)
UAE
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Million)
Rest of Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2020 - 2032, (US$ Million)
8. Competitive Landscape
Takeda Pharmaceutical Company Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Sanofi S.A
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Octapharma AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Swedish Orphan Biovitrum AB
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Baxter
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Biogen Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Bayer AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
CSL Behring
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Ferring B.V.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Pfizer, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Kedrion
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Novo Nordisk A/S
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Grifols S.A.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Sangamo Therapeutics, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Spark Therapeutics, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
9. Section
Research Methodology
About Us
*Browse 36 market data tables and 38 figures on “Middle East and Turkey Hemophilia Treatment Market”- Middle East and Turkey forecast to 2032

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us